The rise of Sildenafil initially fueled a surge for the drug industry, however recent changes present a complicated outlook for investors. Lower-cost competitors are reducing earnings, and ongoing litigation add more risk to the landscape. While some companies could still see gains from adjacent offerings, the broader trajectory suggests a wary … Read More